Two Sigma Advisers
APGE icon

Two Sigma Advisers’s Apogee Therapeutics APGE Stock Holding History

Two Sigma Advisers’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,300
Closed -$274K – 2342
2025
Q2 		$274K Sell
6,300
-61,400
-91% -$2.34M ﹤0.01% 2003
2025
Q1 		$2.53M Sell
67,700
-3,800
-5% -$147K 0.01% 1059
2024
Q4 		$3.24M Buy
71,500
+24,300
+51% +$1.24M 0.01% 892
2024
Q3 		$2.77M Sell
47,200
-5,200
-10% -$249K 0.01% 927
2024
Q2 		$2.06M Buy
52,400
+48,300
+1,178% +$2.34M ﹤0.01% 1177
2024
Q1 		$272K Buy
+4,100
New +$179K ﹤0.01% 2105

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Two Sigma Advisers's APGE Position: Q3 2025 in Review

Two Sigma Advisers sold out of Apogee Therapeutics (APGE) in Q3 2025, closing a stake of 6,300 shares — an estimated $274K sold.

Two Sigma Advisers first reported a position in APGE in Q1 2024 and held it in 6 quarters. The position peaked at $3.24M in Q4 2024. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • Two Sigma Advisers reported no remaining Apogee Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 6,300 Apogee Therapeutics shares in Q3 2025, an estimated $274K.
  • Two Sigma Advisers first reported a position in Apogee Therapeutics in Q1 2024 and held it in 6 quarters.
  • Two Sigma Advisers's Apogee Therapeutics position peaked at $3.24M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.